THE SAFAR CENTER FOR RESUSCITATION RESEARCH:
SEARCHING FOR BREAKTHROUGHS IN THE NEW MILLENNIUM

P. M. Kochanek¹, H. Bayir¹, R. P. Berger², C. E. Dixon³, L. Jenkins³, A. E. Kline⁴,
S. Tisherman⁵, A. K. Wagner⁵, R. S. B. Clark¹

¹ Department of Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, USA
² Department of Pediatrics Children’s Hospital of Pittsburgh Pittsburgh, Pennsylvania, USA
³ Department of Neurological Surgery University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, USA
⁴ Department of Neurological Surgery University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, USA
⁵ Departments of Surgery and Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, USA

This review, written on the occasion of the 70th anniversary of the Institute for General Reanimatology of the Russian Academy of Medical Sciences, provides an update of recent research in the field of resuscitation medicine carried out at the Safar Center for Resuscitation Research at the University of Pittsburgh School of Medicine. Current and recent studies describing bench to bedside investigation in the areas of traumatic brain injury (TBI), cardiopulmonary arrest, hemorrhagic shock, and ultra-novel approaches to resuscitation are discussed. Investigation in TBI across a variety of topics including mechanism of neuronal death, oxidative and nitrative stress, proteomics, adenosine, serotonin, novel magnetic resonance imaging application, inflicted childhood neurotrauma, and TBI rehabilitation is addressed. Research discussed in the program of cardiopulmonary arrest includes optimization of the use of mild hypothermia and novel investigation in experimental asphyxial cardiac arrest. In the program on hemorrhagic shock, our recent work on the application of mild hypothermia to prolong the «golden hour» is presented. Finally, a brief overview of our studies of a novel approach to the resuscitation of exsanguination cardiac arrest using emergency preservation for resuscitation (EPR) is provided. Key Words: Traumatic Brain Injury, Resuscitation, Child Abuse, Inflicted Childhood Neurotrauma, Hemorrhagic Shock, Emergency Preservation and Resuscitation, Apoptosis, Adenosine, Proteomics.

Introduction

First, let me congratulate Dr. Victor Moroz on the occasion of the the 70th anniversary of the Institute for General Reanimatology of the Russian Academy of Medical Sciences. It is a truly amazing accomplishment and one that I know would have had special meaning to the late Dr. Peter Safar. There is a rich and special history of interaction between the late Drs. Peter Safar and Dr. Vladimir Negovsky, two giants in the history of resuscitation. To commemorate your anniversary celebration, I have provided this review article, which presents a very brief historical overview of the interface between Drs. Safar and Negovsky, followed by a description of the evolution of the International Resuscitation Research Center (IRRC) at the University of Pittsburgh School of Medicine into the Safar Center for Resuscitation Research—including an overview of some of our current programs along with a selection of interesting recent findings from our center.

The Safar-Negovsky Legacy

On September 5th 1962, Drs. Peter Safar chaired a panel discussion at the First European Anesthesiology Congress in Vienna, Austria on the topic of «Controversial aspects of resuscitation». Despite the challenges imposed by the cold war in the early 1960s, Dr. Safar invited Dr. Vladimir Negovsky to participate [1]—having read one of the English translated versions of Dr. Negovsky’s work. That meeting began a lifelong friendship and mutual admiration between the two individuals who arguably became the most important figures in the history of modern resuscitation. Dr. Safar was impressed by four seminal aspects of the pioneering work of Dr. Negovsky [2—4, namely 1) his establishing a resuscitation research center as early as 1937, 2) his early documentation of the use of centripetal intra-arterial blood pumping and mechanical ventilation to resuscitate that was initially suggested by Russian physician Andreev in 1913, 3) his coining of the term «reanimatology» and 4) his description of the concept of «post-resuscitation disease». Dr. Safar’s own pioneering work in resuscitation (reviewed in 5) included the development of mouth-to-mouth resuscitation, the assembly and dissemination of CPR, his work on the application of mild hypothermia in cerebral resuscitation, his key role in the development of emergency medicine services for field resuscitation (which also included design of the modern cabin configuration of the ambulance), seminal studies on the pathomechanisms of human death in natural and man-made disasters, and ultimately, his spearheading the development of novel approaches to resuscitation such as emergency preservation and resuscitation (EPR). I believe that the mutual respect and sharing of ideas between these two colleagues influenced Negovsky to become more treatment oriented and Safar to further study pathophysiologic mechanisms [1] (Figure 1). The passing of these two giants and great leaders in resuscitation — both during the first week in August 2003 — represented a huge loss for the resuscitation community. However, their work has provided us with an incredibly rich foundation upon which new approaches can be developed to «save hearts and brains too good to die».
Transition from the IRRC to the Safar Center

In 1994, Dr. Peter Safar stepped down as director of the IRRC, to focus his efforts more on his research and a number of other projects. At that time, Dr. Safar had established research programs at the IRRC in the areas of cardiopulmonary arrest, hemorrhagic shock, and disaster medicine. I had the good fortune of being named director after a local competition between three faculty investigators in the Department of Anesthesiology and Critical Care Medicine at the University of Pittsburgh. Over the past 12 years, several new programs have been developed at the center and the landscape of several of the existing programs has evolved. Currently, we have programs in traumatic brain injury (TBI), cardiopulmonary arrest, hemorrhagic shock, and ultra-advanced resuscitation approaches such as EPR. Several important new investigators have been added to the center, and a number of key collaborators are involved. New and/or enhanced roles for molecular biology, free radical biology, proteomics, CNS injury models, and rehabilitation research have emerged. Our center has a multidisciplinary faculty which spans the departments of Critical Care Medicine, Neurological Surgery, Pediatrics, Surgery, Physical Medicine and Rehabilitation, Emergency Medicine, Anesthesiology, and Pathology. A synthesis of some of the most exciting and important findings within each of these programs is provided below. Finally, one former program is currently inactive, and that is the program in disaster medicine.

Current Investigation at the Safar Center for Resuscitation Research

Traumatic Brain Injury: Bench to bedside

This represents a new area of research that has developed during the past 10 years. It has been the most productive area of investigation in our center and includes work as principal investigator by eight faculty investigators, and numerous important collaborators and trainees. Current studies in our center are focused on mechanisms in the evolution of secondary damage including delayed neuronal death, oxidative and nitrative stress, dopamine systems, poly-ADP ribose polymerase (PARP), kinase- and phosphatase-mediated events, serotonin pathways, and endogenous neuroprotectants such as adenosine. We and our collaborators have taken advantage of a number of important new tools in this work on TBI, including the use of a contemporary model of experimental TBI-controlled cortical impact (CCI), the application of novel magnetic resonance imaging (MRI) tools such as perfusion imaging and non-invasive assessment of macrophage accumulation in injured brain, novel proteomic and oxidative lipidomic approaches, and in vivo electrochemical monitoring techniques like fast scan cyclic voltammetry; among others methods. We have used the CCI model of TBI in both rats and mice for over sixty studies in experimental TBI. This model was developed for use in rats by Dr. C. Edward Dixon, one of the Safar Center faculty [6], and is both highly reproducible, and well characterized. In addition, we have developed several modifications of this model, most notably the use of combined TBI plus secondary hypoxemia [7] which models the important combination of these insults that is often observed clinically after TBI [8]. Finally, our group has led the way in linking bench-bedside in the study of cellular and molecular mechanism of secondary damage and repair in human TBI. We have accomplished this using two important resources, assessing biochemical and molecular markers in cerebrospinal fluid (CSF) drained through ventriculostomy catheters in the treatment of intracranial hypertension in patients (both adults and children) with severe TBI [reviewed in 9], and by performing western analysis and immunohistochemistry of brain tissue resected emergently from critically ill patients with severe TBI in the treatment of refractory intracranial hypertension and impending herniation [10-12].

Mechanism of neuronal death

This area of investigation has been the focus of Safar Center investigator, Dr. Robert Clark—who has contributed a number of important reports in both experimental and clinical TBI. Dr. Clark’s most significant contributions in this area have included the first documentation of caspase-3 and caspase-1 activation in human head injury [10] (Figure 2), and early descriptions of the role of both caspase activation and apoptosis-initiating factor (AIF) release in experimental TBI [13, 14]. Most recently Dr. Clark and his group have published two reports in human TBI that have substantially advanced our knowledge in this area. First, Zhang et al [12] reported that the important cell survival pathway linked to protein kinase B...
PKB (also known as Akt) is activated in human TBI. PKB, when activated, is phosphorylated and inhibits the intrinsic (mitochondrial) pathway of apoptosis. This is believed to be accomplished by PKB-mediated phosphorylation and inactivation of downstream death signals such as BAD and by phosphorylation and activation of the pro-survival signal cyclic AMP response element binding protein (CREB). Using brain tissue samples from 15 patients with severe TBI, Dr. Clark’s group convincingly demonstrated that PKB and its downstream signals are phosphorylated and thus activated in human head injury, supporting a role for this important pathway and suggesting that it may be a target for therapeutic manipulation.

These findings have taken on even greater significance given the recent work from the laboratory of Dr. Gary Steinberg suggesting that mild therapeutic hypothermia may confer some of its benefit through the enhancement of this pathway [15].

A second important recent publication from Dr. Clark’s laboratory by Satchell et al. [16], reported that levels of the key cellular apoptosis trigger cytochrome C are increased in CSF of infants and children with severe TBI, particularly in victims of inflicted childhood neurotrauma (i.e., child abuse or “shaken baby syndrome”). Because release of cytochrome C has been shown to be a pivotal trigger of the apoptotic cascade in a number of experimental systems, this study of 67 infants and children suggests that delayed neuronal death plays an important role in pediatric TBI, and that this pathway may be a particularly important therapeutic target in victims of child abuse. Targeting delayed neuronal death appears to represent an important therapeutic target for the development of new therapies for TBI, particularly in infants and young children.

**Oxidative and nitritative stress**

Dr. Hulya Bayir of the Safar Center, in collaboration with Dr. Valerian Kagan, at the University of Pittsburgh Center for Free Radical and Antioxidant Health, have carried out a series of studies over the past 5 years that has contributed significantly to our understanding of the role of oxidative and nitritative stress in experimental and clinical TBI [17–24]. Using a comprehensive battery of markers of oxidative stress, Bayir et al. [16] reported marked increases in lipid peroxidation and depletion of endogenous antioxidants such as ascorbate and total antioxidant...
Bayir — in collaboration with Dr. David Adelson and his recent randomized controlled clinical trial of the use of mild to moderate hypothermia in infants with severe TBI, demonstrated that cooling significantly attenuated the loss of antioxidants in infants with severe TBI [22] — suggesting that this mechanism accompanies the reduction in intracranial pressure that is known to be produced with the use of mild and moderate hypothermia in clinical TBI. Finally, in recent studies in our laboratory, Dr. Bayir has demonstrated, using neuronal nitric oxide synthase knockout mice, that the nitric oxide pathway in neurons and likely specifically in mitochondria contribute importantly to the nitration and inactivation of the important mitochondrial antioxidant enzyme Manganese superoxide dismutase (MnSOD) [23, 24]. She similarly reported that MnSOD nitration and inactivation occur in confusion samples from humans with severe TBI [23]. This is another example of the type of bench-to-bedside work that we feel is important to enhancing our understanding of cellular and molecular mechanisms of secondary injury in severe TBI. Additional research on the role of oxidative and nitritative stress in TBI is warranted.

Proteomics applications
One of the best methods currently available to try to unravel the mechanism of secondary injury and repair in the injured brain after TBI or cardiac arrest is the use of proteomics. Using both 2-D gel and high-throughput multiblot approaches allows the simultaneous investigation of many proteins, along with the examination of critical protein post-translational modifications such as phosphorylation (Figure 4). Dr. Larry Jenkins and his associates in our center have contributed the initial application of this contemporary technology to the field of experimental TBI [26], the first use of this method in a developmental TBI model [27], and early use in clinical TBI [28]. In a manuscript in press [27], Dr. Jenkins’ group used a 2D difference gel electrophoresis (DIGE) method to study the response to experimental brain injury in the rat hippocampus at 14 days after CCI injury in developing (17 day-old) rats. Changes in a large number of important proteins across numerous functional categories such as energy metabolism and mitochondrial function, synaptic function, oxidative stress, and cell stress and chaperone proteins were identified. For example, 30% decreases in pyruvate dehydrogenase E1 beta and alpha subunits were noted, while the glial stress protein GFAP was increased over 300-fold. More recently, Gao et al [28] used a 2D gel approach to study CSF from infants and children with TBI reserve in CSF samples in children with severe TBI. Striking and concerning was the extent and progressive nature of the ascorbate depletion in these patients over the initial 5 days after severe TBI (Figure 3). This report strongly suggests that one of the mechanisms underlying the well recognized heightened vulnerability of patients with severe TBI to secondary brain insults in the intensive care unit, reported by Gopinath et al [25], is loss of antioxidant defenses. More recently, in preliminary studies, Dr. Jenkins et al [27] used a 2D difference gel approach to study CSF from infants and children with TBI. From Jenkins et al [27] with permission.

Figure 3. Effect of severe TBI on the antioxidant ascorbate concentration in CSF of infants and children. Ascorbate concentrations were 3-, 8-, and 10-fold lower in subjects with TBI on d 1, d 2, and d 5–7, respectively, compared with controls (* p<0.05 vs control, # p<0.05 vs TBI d 1). These findings strongly support that the injured brain is depleted of endogenous antioxidants and may be vulnerable to secondary oxidative insults in the intensive care unit. From Bayir et al (10) with permission.

Figure 4. Proteomic assessment using large-format 2D immunoblots showing a reduction in the number of phosphoproteins after experimental TBI in rats (135 spots) versus sham rats (209 spots). In addition to such general changes, spot candidates for a number of known protein substrates, such as forkhead transcription factors (FKHR, FKHR1), phosphodiesterase-3-beta (PDE-3B), glucose transporter protein 3 (GLUT3), and glucose transporter protein 4 (GLUT4), were proposed on the basis of observed Mr and pI values. Comparable spot candidates for FKHR, and FKHR1 phospho-immunoreactivity were not seen after CCI, with considerable loss of phosphor-immunoreactivity in GLUT3 and GLUT4. This powerful proteomic method demonstrates the ability to simultaneously assess changes in multiple phosphorylated proteins after experimental TBI. From Jenkins et al [26] with permission.
either inflicted (child abuse) or non-inflicted (accidental) TBI. He demonstrated unique increases in the acute phase reactants such as haptoglobin isoforms in infants with accidental but not inflicted TBI. This suggests that factors such as a delay in presentation or chronic or repeated injury may blunt the traditional acute phase response in victims of TBI from child abuse.

Adenosine

Our group, in collaboration with Dr. Edwin Jackson of the University of Pittsburgh Center for Clinical Pharmacology, has carried out a number of studies demonstrating marked increased in levels of adenosine in brain interstitial fluid and CSF after both experimental and clinical TBI [29–32]. We have also characterized some of the putative effects of adenosine production in the injured brain, in both our model systems and in humans [31, 33–36]. Adenosine is believed to play a critical endogenous neuroprotectant role through effects at multiple receptors including A1, A2a, A2b, and A3. For example, adenosine, formed during the breakdown of ATP in ischemic brain regions has important anti-excitotoxic and anti-convulsant effects in brain in some model systems, while, effects of adenosine at A2a and A2b receptors can, among other effects, increase cerebral blood flow (CBF) [37, 38]. One can readily envisage that reduced metabolic demands and improved CBF represent valuable endogenous protective effects early after brain injury from either trauma or ischemia.

We recently published two studies that provide insight into the potential neuroprotective role for adenosine in TBI. First, we reported that early after CCI, adenosine A1 receptor knockout mice develop lethal status epilepticus [36]. Status epilepticus has not been noted by us or others in numerous studies with the mouse CCI model. Nevertheless, it occurs in the A1 receptor knockout mouse even when moderate injury levels are used, and is seen independent of gender. This finding supports a powerful anti-convulsant effect of adenosine -mediated by effects at the A1 receptor-after experimental TBI, and may provided important clues toward the development of highly targeted anti-excitotoxic therapies. We have also recently reported that non-selective and A2a-selective adenosine agonists confer powerful CBF promoting effects in both the normal brain and early after CCI in rats [35] (Figure 5). It is well recognized that early after experimental and clinical TBI, CBF is reduced [39, 40]. This has suggested posttraumatic hypoperfusion or ischemia as a putative therapeutic target. Using novel perfusion MRI via the continuous arterial spin-labeling method, we demonstrated that CBF could be normalized early after injury by local injection of non-selective adenosine agonists [35]. Thus, optimal manipulation of the adenosine cascade may represent an avenue for the early post-resuscitation phase in human head injury and is an area of active investigation at our center.

Serotonin 1A receptor agonists

Another area of investigation targeting pharmacological manipulation of injured brain after severe TBI is via the serotonin transmitter system. Recent work by Dr. Anthony Kline in our center [41–43] has demonstrated beneficial effects of serotonin 1A receptor agonists against both neuronal cell death and functional impairments in rats after CCI. Agents such as either repinotan or 8 hydroxy DPAT-administered after the injury-were shown to be effective [41–43]. Although the mechanism or mechanisms underlying the beneficial effects of serotonin 1A receptor agonists in TBI remain to be determined, it may be more than coincidence that these agents share important anti-excitotoxic properties with adenosine and adenosine A1 receptor agonists, including the ability to hyperpolarize neurons, decrease glutamate release via actions at presynaptic glutamatergic terminals, and inhibit sodium channels. This suggests that excitotoxic pathways are of special importance early after TBI. Finally, the possibility of synergism of serotonin and
adenosine targeting therapies in experimental or clinical TBI has not been investigated but might represent an intriguing opportunity.

**MRI applications in experimental TBI**

MRI is a powerful tool for the investigation of experimental TBI and cardiac arrest. We have collaborated extensively with Dr. Chien Ho and his research group at the Pittsburgh NMR center for biomedical research at Carnegie Mellon University. We have used novel perfusion MRI by the continuous arterial spin-labeling method to measure CBF in rat brain. This non-invasive method, which uses arterial water as the label, is highly advantages in that it can generate serial maps of CBF — allowing for temporal and regional assessment. In a series of studies, we have assessed CO₂ reactivity after CCI [44], early posttraumatic hypoperfusion [39], the effects of anesthesia on CBF [45], serial assessment of CBF and blood-brain barrier permeability [46], study of CBF at long outcome times-as late as one year after injury [47], and the aforementioned studies of the effect of adenosine receptor agonists [33, 35]. This year, we expanded the application of this non-invasive method of CBF assessment to the studies in mice [48]. Successful adaptation of this method to the study of mice allows for the investigation of a wealth of transgenic and knockout animals, and we believe, will provide considerable insight into the contribution of posttraumatic ischemia to the evolution of secondary damage after TBI.

**Inflicted childhood neurotrauma**

An important problem in the field of pediatric TBI is inflicted childhood neurotrauma (child abuse, shaken baby syndrome). By assessing CSF from infants and children with severe TBI, it has become clear that victims of inflicted childhood neurotrauma often exhibit a unique biochemical profile versus victims of accidental injuries (motor vehicle accidents, falls, etc.). As previously discussed, victims of inflicted childhood neurotrauma may exhibit a number of unique biochemical and molecular features such as 1) a failure to mount some aspects of the acute phase response to injury such as an increase in haptoglobin levels [28], 2) accentuated delayed neuronal death as reflected by a late rise in cytochrome c levels [16] and neuron specific enolase (NSE) levels [49] in CSF, and 3) exaggerated stress response as reflected by high CSF levels of heat shock proteins such as HSP 70 [50], among others. These findings may reflect chronic injury, delay in presentation, a propensity toward apoptosis related to the young age of these victims (they are almost always infants), and/or to the frequent occurrence of hypoxemic episodes in these patients from untreated seizures or apnea [51]. Our findings suggest that treatment of inflicted childhood neurotrauma in infants may benefit from therapies effective in hypoxic-ischemic encephalopathy (such as mild hypothermia) and possibly therapies targeting apoptosis — which may be responsible for delayed neuronal death.

We have also measured biomarkers of brain injury (such as NSE) in serum in addition to CSF in an attempt to identify victims of mild or moderate inflicted TBI in an attempt to prevent misdiagnosis — which is an important problem for general pediatricians or emergency medicine physicians. In a recent report, Dr. Rachel Berger, working on this area at our center and Children’s Hospital of Pittsburgh measured serum NSE in 98 infants who presented with non-specific symptoms that are often consistent with those seen in missed cases of inflicted childhood neurotrauma (such as vomiting without diarrhea or irritability) [32]. There was an increase in serum NSE in 79% of the children diagnosed with inflicted childhood neurotrauma and in 80% of the children who, in retrospect, may have been additional missed cases. The use of serum biomarkers, such as NSE, may represent an important new diagnostic adjunct for use in this setting [reviewed in 53].

**The link between research in acute TBI and rehabilitation**

Our center has traditionally focused on the acute and sub-acute phases after CNS injury — those most germane to resuscitation. However, faculty in our center in the Departments of both Neurological Surgery and Physical Medicine and Rehabilitation have been focused recently, in part, on more delayed phases after TBI. This was suggested as an important area for future research by Professor Vladimir Negovsky in his «Essays on Reanimatology» in 1980 [4]. Dixon et al [54] reported on sustained cognitive deficits in rats over a one year follow-up period after TBI produced by CCI. More recently Drs. Amy Wagner and Anthony Kline have been studying the effect of environmental enrichment on long-term cognitive outcome in rats after CCI. Environmental enrichment represents an interesting strategy that models the use of rehabilitation in the clinical setting. Environmental enrichment has powerful beneficial effects on outcome. Wagner et al [55] reported that the beneficial effect of environmental enrichment on cognitive outcome was observed only in males after CCI in rats implying important gender differences. Subsequent studies suggest that the environmental enrichment effects on dopamine systems and neurotrophin production after experimental TBI are also, in part, gender specific [56, 57]. These studies represent on aspect of a novel approach to studying therapies in experimental TBI, namely, assessment of therapies relevant to rehabilitation in the sub-acute or chronic phases after injury. Both drugs and cellular therapies (such as stem cells) may have important potential in helping the brain re-wire after injury.

**Cardiopulmonary arrest**

Optimization of therapeutic hypothermia after cardiopulmonary arrest

A major focus of investigation in cardiopulmonary arrest at the Safar Center is in optimizing the...
use of therapeutic hypothermia. Dr. Safar and a number of other investigators used therapeutic hypothermia in the late 1950s and early 1960s. Indeed, therapeutic hypothermia was incorporated into the «ABCs» of resuscitation in the early 1960s (Figure 6) [58]. However, in that era, moderate (28—32°C) rather than mild (23—35°C) hypothermia was used and often for too long of a duration-leading to infections and other complications. Along with the classic paper of Busto et al [59], Dr. Peter Safar’s work in clinically realistic experimental cardiac arrest launched the re-assessment of mild cooling—which has led to positive clinical trials in both adults and infants. We used a scenario that included ventricular fibrillation (VF) followed by 3 min of no flow, 7 min of basic life support (BLS) and 10 additional min of VF with simulated unsuccessful advanced cardiac life support (ACLS). We then randomized dogs to 20 min of either continued ACLS at normothermia, or moderate hypothermia induced via venovenous extracorporeal shunt cooling. Therapeutic hypothermia induced during the arrest produced a dramatic beneficial effect-namely, normal outcomes. In contrast, dogs maintained normothermic developed multiple organ failure and remained comatose [66]. More recently, we reported that delaying the application of hypothermia from 10 min to 20 min in the resuscitation greatly reduced its effectiveness—suggesting a critical time window for the optimal intra-arrest application of cooling [67]. Coupled with the published reports on success of post-arrest cooling [60, 61] and the recent work of Bernard et al [68], our findings suggests that to optimize outcomes after cardiac arrest, cooling during resuscitation should be promptly initiated-probably with a cold intravenous bolus—and continued for 12—24 hours after resuscitation.

Asphyxial arrest—novel mechanistic insight and treatment

Related to the strong link of several of our center investigators to pediatric critical care medicine and pediatric neurointensive care, there is considerable research in the area of pediatric resuscitation. Dr. Ericka Fink, working in the laboratory of Robert Clark has developed a new rat model of asphyxial cardiopulmonary arrest mimicking the pediatric condition [69]. In that model, anesthetized rats 17 days of age are subjected to an asphyxial insult that rapidly leads to full cardiopulmonary arrest. A total insult duration of 8.5 min is used, and results — after resuscitation using chest compressions, epinephrine, and sodium bicarbonate administration—in survival with neuronal death in selectively vulnerable brain regions.

Figure 6. Initial description of the ABCs of resuscitation by Dr. Peter Safar in this classic publication in the Journal of the Iowa Medical Society. Note that Dr. Safar recommended the use of hypothermia for victims that fail to promptly recover in this early 1960s, and had already incorporated this approach into his clinical decision tree.
It has been shown that mild hypothermia, induced with intravenous infusion of room temperature saline, improves survival in a clinically relevant model of hemorrhagic shock and trauma. However, the use of iced saline in this model had detrimental effects. These findings suggest that optimal methods for induction of hypothermia must be addressed for each potential indication, e.g., cardiac arrest versus TBI versus hemorrhagic shock.

Emergency preservation and resuscitation (EPR)

Exsanguination cardiac arrest has an extremely poor prognosis [79], likely related at least in part to the limited effectiveness of conventional resuscitation methods (i.e., CPR, BLS, and ACLS) in this setting. This form of arrest is common among combat casualties and can also be seen in some cases of civilian trauma. As previously discussed, some of Dr. Negovsky’s pioneering work focused on the problem of exsanguination cardiac arrest and used an intraarterial injection of oxygenated blood plus epinephrine targeting the resuscitation of exsanguinated wounded soldiers (reviewed in [3]). During the last 15 years of his life, Dr. Safar worked to develop a novel approach to this otherwise refractory form of arrest. He initially termed this approach «Suspendedanimation for delayed resuscitation» [80]. The approach was developed in a dog model of exsanguination cardiac arrest and used a rapid aortic flush of ice cold saline (with jugular venous drainage) to promptly (within 15–20 minutes) achieve a state of profound hypothermic preservation (Figure 8). Successful emergency preservation for periods of between 1 and 3 hours would allow transport of the casualty to the far forward treatment facility in the military setting or trauma bay in the civilian setting where surgical repair could take place followed by delayed resuscitation using cardiopulmonary bypass. In a series of reports, we were able to achieve initially—within 30 min and 1 hour of preservation and eventually —2 hours of preservation with favorable results.
outcome [81—83]. Some of our most recent studies suggest that 3 hours of EPR induced during exsanguination cardiac arrest may be achievable [84].

A recent publication on this topic by our center is noteworthy. Wu et al [85] tested whether or not this approach could be successful if exsanguination cardiac arrest was preceded by about 2 hours of hemorrhagic shock. In that study, good neurological outcome was achieved after a 1 hour period of hypothermic preservation even if it was preceded by 2 hours of hemorrhagic shock. Favorable outcome could only be achieved if the period of preservation was followed with 36 hours of mild hypothermia followed by slow re-warming. Dr. Drabek in our group has also recently developed a rat model of EPR to both carry out molecular studies of the mechanisms of hypothermic preservation and to screen novel therapies [86].

This novel approach to resuscitation has been named EPR in Dr. Safar’s honor and may represent the new CPR for cases of refractory arrest—particularly those due to exsanguination. Finally, recent studies by Behringer in Vienna have begun to apply this approach to cases of refractory normovolemic cardiac arrest [87] and have built on Dr. Safar’s suggestions of an even broader potential application of EPR. A multi-center clinical feasibility trial of EPR in the setting of civilian trauma resulting in exsanguination cardiac arrest is in the planning stages, and an initial consortium meeting of interested trauma centers was held by Dr. Tisherman in 2005 in Pittsburgh.

Conclusions and future directions

Building on the remarkable foundation laid by Dr. Peter Safar, and capitalizing on many of the important clues in the seminal work of Dr. Vladimir Negovsky, the Safar Center for Resuscitation Research continues to better understand the pathobiology of clinical conditions that require resuscitation, and ultimately improve therapies. Over the past 12 years, the scope of the work at the Safar Center has expanded to include programs in the areas of TBI and rehabilitation, and the importance of pediatric CNS injury and resuscitation have also increased in scope. Future investigation at the Safar Center, I believe, will include additional work on mechanisms in the evolution of secondary damage after TBI, cardiac arrest, and hemorrhagic shock, and development and translation of novel therapies for these conditions. New tools such as proteomics, lipidomics, genomics and advanced MRI applications are important to our ability to better understand the cybernetic post-resuscitation disease, first introduced by Dr. Negovsky, which follows these severe insults. We are also beginning to put substantial effort into studying blast injury and the combination of TBI and hemorrhagic shock. These conditions are important, albeit very unfortunate, consequences of terrorist attacks with improvised explosive devices in both the military and civilian sectors [88, 89]. We are currently investigating novel resuscitation fluids and therapies in experimental models of these important conditions. We are also placing increased emphasis on the importance of rehabilitation, and the need for research in that area. Finally, we hope to pursue additional work in ultra-advanced resuscitation techniques, including EPR, and look forward to the challenge of an initial clinical trial in exsanguination cardiopulmonary arrest.

Acknowledgement

This article is written in honor of the late Drs. Peter Safar and Vladimir Negovsky. Dr. Kochanek is supported by the National Institutes of Health, USA, National Institute of Neurological Disorders and Stroke (NS 30318, NS 38087), the National Institute of Child Health and Human Development (T32 HD40686) the United States Army (W81XWH-06-1-0247), the Centers for Disease Control and Prevention, USA (University of Pittsburgh Center for Injury Research and Control). We also thank the Laerdal Foundation for Acute Medicine for the support of many of trainees who carried out the studies presented in this review.


